{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:54:09Z","timestamp":1790974449139,"version":"4.1.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["25JRRA584"],"award-info":[{"award-number":["25JRRA584"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009572","name":"Health and Family Planning Commission of Gansu","doi-asserted-by":"publisher","award":["GSWSQNPY2025-15"],"award-info":[{"award-number":["GSWSQNPY2025-15"]}],"id":[{"id":"10.13039\/501100009572","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08043-y","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:33:56Z","timestamp":1774420436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["From feasibility to translational pathways: a bibliometric and knowledge-mapping analysis of urine-based liquid biopsy in urologic cancers (2015\u20132025)"],"prefix":"10.1186","volume":"24","author":[{"given":"Hanlin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsheng","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"3","key":"8043_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834. PubMed PMID: 38572751.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"8043_CR2","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.euo.2025.05.007","volume":"8","author":"DKW Leung","year":"2025","unstructured":"Leung DKW, Wong CHM, Ko ICH, Siu BWH, Liu AQY, Meng HYH, et al. Global Trends in the Incidence, Mortality, and Risk-attributable Deaths for Prostate, Bladder, and Kidney Cancers: A Systematic Analysis from the Global Burden of Disease Study 2021. Eur Urol Oncol. 2025;8(6):1533\u201343. https:\/\/doi.org\/10.1016\/j.euo.2025.05.007. PubMed PMID: 40441940.","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"8043_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/md20080466","volume":"20","author":"S Ahmed","year":"2022","unstructured":"Ahmed S, Alam W, Jeandet P, Aschner M, Alsharif KF, Saso L, et al. Therapeutic Potential of Marine Peptides in Prostate Cancer: Mechanistic Insights. Mar Drugs. 2022;20(8):466. https:\/\/doi.org\/10.3390\/md20080466. PubMed PMID: 35892934; PubMed Central PMCID: PMC9330892.","journal-title":"Mar Drugs"},{"issue":"2","key":"8043_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, Van Den Bergh RCN, Briers E, Van Den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86(2):148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03. .027 PubMed PMID: 38614820.","journal-title":"Eur Urol"},{"issue":"6","key":"8043_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O, Comp\u00e9rat E, Dominguez-Escrig JL, Liedberg F, et al. European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)\u2014A Summary of the 2024 Guidelines Update. Eur Urol. 2024;86(6):531\u201349. https:\/\/doi.org\/10.1016\/j.eururo.2024.07. .027 PubMed PMID: 39155194.","journal-title":"Eur Urol"},{"issue":"6","key":"8043_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo","volume":"87","author":"A Bex","year":"2025","unstructured":"Bex A, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update. Eur Urol. 2025;87(6):683\u201396. https:\/\/doi.org\/10.1016\/j.eururo. 2025.02.020 PubMed PMID: 40118739.","journal-title":"Eur Urol"},{"issue":"6","key":"8043_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/1061186X.2024.2347358","volume":"32","author":"S Ahmad","year":"2024","unstructured":"Ahmad S, Raza K. An extensive review on lung cancer therapeutics using machine learning techniques: state-of-the-art and perspectives. J Drug Target. 2024;32(6):635\u201346. 2024.2347358 PubMed PMID: 38662768.","journal-title":"J Drug Target"},{"key":"8043_CR8","doi-asserted-by":"publisher","first-page":"100146","DOI":"10.1016\/j.jlb.2024.100146","volume":"4","author":"M Boukovala","year":"2024","unstructured":"Boukovala M, Westphalen CB, Probst V. Liquid biopsy into the clinics: Current evidence and future perspectives. J Liquid Biopsy. 2024;4:100146. https:\/\/doi.org\/10.1016\/j.jlb.2024.100146.","journal-title":"J Liquid Biopsy"},{"issue":"224","key":"8043_CR9","doi-asserted-by":"publisher","first-page":"ra22424","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):ra22424\u201322424. https:\/\/doi.org\/10.1126\/scitranslmed.3007094.","journal-title":"Sci Transl Med"},{"issue":"4","key":"8043_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338. https:\/\/doi.org\/10.1038\/nrc.2017.7.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"8043_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic \u2014 implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297\u2013312. https:\/\/doi.org\/10.1038\/s41571-020-00457-x.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"8043_CR12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41416-022-01776-9","volume":"127","author":"M Garc\u00eda-Pardo","year":"2022","unstructured":"Garc\u00eda-Pardo M, Makarem M, Li JJN, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. Br J Cancer. 2022;127(4):592\u2013602. https:\/\/doi.org\/10.1038\/s41416-022-01776-9. PubMed PMID: 35347327; PubMed Central PMCID: PMC9381753.","journal-title":"Br J Cancer"},{"issue":"11","key":"8043_CR13","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.3390\/cancers13112652","volume":"13","author":"M Oshi","year":"2021","unstructured":"Oshi M, Murthy V, Takahashi H, Huyser M, Okano M, Tokumaru Y, et al. Urine as a Source of Liquid Biopsy for Cancer. Cancers. 2021;13(11):2652. https:\/\/doi.org\/10.3390\/cancers13112652. PubMed PMID: 34071230; PubMed Central PMCID: PMC8199052.","journal-title":"Cancers"},{"key":"8043_CR14","doi-asserted-by":"publisher","first-page":"115027","DOI":"10.1016\/j.biopha.2023.115027","volume":"165","author":"S Wu","year":"2023","unstructured":"Wu S, Li R, Jiang Y, Yu J, Zheng J, Li Z, et al. Liquid biopsy in urothelial carcinoma: Detection techniques and clinical applications. Biomed Pharmacother. 2023;165:115027. https:\/\/doi.org\/10.1016\/j.biopha.2023.115027.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"8043_CR15","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1002\/ijc.34434","volume":"152","author":"S Jordaens","year":"2023","unstructured":"Jordaens S, Zwaenepoel K, Tjalma W, Deben C, Beyers K, Vankerckhoven V, et al. Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods. Intl J Cancer. 2023;152(10):2186\u2013205. https:\/\/doi.org\/10.1002\/ijc.34434. PubMed PMID: 36647333.","journal-title":"Intl J Cancer"},{"issue":"3","key":"8043_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.32607\/20758251-2015-7-3-48-54","volume":"7","author":"OE Bryzgunova","year":"2015","unstructured":"Bryzgunova OE, Laktionov PP. Extracellular Nucleic Acids in Urine: Sources, Structure, Diagnostic Potential. Acta Naturae. 2015;7(3):48\u201354. https:\/\/doi.org\/10.32607\/20758251-2015-7-3-48-54. PubMed PMID: 26483959; PubMed Central PMCID: PMC4610164.","journal-title":"Acta Naturae"},{"issue":"7","key":"8043_CR17","doi-asserted-by":"publisher","first-page":"e12093","DOI":"10.1002\/jev2","volume":"10","author":"U Erdbr\u00fcgger","year":"2021","unstructured":"Erdbr\u00fcgger U, Blijdorp CJ, Bijnsdorp IV, Borr\u00e0s FE, Burger D, Bussolati B, et al. Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles. J Extracell Vesicle. 2021;10(7):e12093. https:\/\/doi.org\/10.1002\/jev2. 12093 PubMed PMID: 34035881; PubMed Central PMCID: PMC8138533.","journal-title":"J Extracell Vesicle"},{"issue":"6","key":"8043_CR18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.euf.2024.05.024","volume":"10","author":"M Silva-Ferreira","year":"2024","unstructured":"Silva-Ferreira M, Carvalho JA, Salta S, Henriques TS, Pereira Rodrigues P, Monteiro-Reis S, et al. Diagnostic Test Accuracy of Urinary DNA Methylation-based Biomarkers for the Detection of Primary and Recurrent Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2024;10(6):922\u201334. https:\/\/doi.org\/10.1016\/j.euf.2024.05.024. PubMed PMID: 38897871.","journal-title":"Eur Urol Focus"},{"issue":"6","key":"8043_CR19","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2016.12","volume":"71","author":"E Christensen","year":"2017","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Nordentoft I, H\u00f8yer S, Van Der Keur K, Van Kessel K, et al. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. Eur Urol. 2017;71(6):961\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2016.12. .016 PubMed PMID: 28069289.","journal-title":"Eur Urol"},{"key":"8043_CR20","doi-asserted-by":"publisher","first-page":"597486","DOI":"10.3389\/fonc.2020.597486","volume":"10","author":"Y Xu","year":"2021","unstructured":"Xu Y, Ma X, Ai X, Gao J, Liang Y, Zhang Q, et al. A Urine-Based Liquid Biopsy Method for Detection of Upper Tract Urinary Carcinoma. Front Oncol. 2021;10:597486. https:\/\/doi.org\/10.3389\/fonc.2020.597486. PubMed PMID: 33634022; PubMed Central PMCID: PMC7901537.","journal-title":"Front Oncol"},{"issue":"10","key":"8043_CR21","doi-asserted-by":"publisher","first-page":"6755","DOI":"10.1111\/jcmm.14553","volume":"23","author":"S Song","year":"2019","unstructured":"Song S, Long M, Yu G, Cheng Y, Yang Q, Liu J, et al. Urinary exosome miR-30c\u20105p as a biomarker of clear cell renal cell carcinoma that inhibits progression by targeting HSPA5. J Cell Mol Medi. 2019;23(10):6755\u201365. https:\/\/doi.org\/10.1111\/jcmm.14553. PubMed PMID: 31342628; PubMed Central PMCID: PMC6787446.","journal-title":"J Cell Mol Medi"},{"issue":"10","key":"8043_CR22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.urolonc.2025.07.034","volume":"43","author":"P Pisapia","year":"2025","unstructured":"Pisapia P, Pepe F, Russo G, Capoluongo R, Coppola M, Giudice FD, et al. Liquid biopsy testing in urological cancers: Focus on urine. Urologic Oncology: Seminars Original Investigations. 2025;43(10):553\u201364. https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.034.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"issue":"12","key":"8043_CR23","doi-asserted-by":"publisher","first-page":"e12158","DOI":"10.1002\/jev2","volume":"10","author":"K Barreiro","year":"2021","unstructured":"Barreiro K, Dwivedi OP, Valkonen S, Groop P, Tuomi T, Holthofer H, et al. Urinary extracellular vesicles: Assessment of pre-analytical variables and development of a quality control with focus on transcriptomic biomarker research. J Extracell Vesicle. 2021;10(12):e12158. https:\/\/doi.org\/10.1002\/jev2. 12158 PubMed PMID: 34651466; PubMed Central PMCID: PMC8517090.","journal-title":"J Extracell Vesicle"},{"issue":"17","key":"8043_CR24","doi-asserted-by":"publisher","first-page":"7872","DOI":"10.7150\/thno.44634","volume":"10","author":"CK Chen","year":"2020","unstructured":"Chen CK, Liao J, Li MS, Khoo BL. Urine biopsy technologies: Cancer and beyond. Theranostics. 2020;10(17):7872\u201388. https:\/\/doi.org\/10.7150\/thno.44634. PubMed PMID: 32685026; PubMed Central PMCID: PMC73590941.","journal-title":"Theranostics"},{"issue":"1","key":"8043_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3978\/j.issn.1000-9604.2016.01.05","volume":"28","author":"Z Yang","year":"2016","unstructured":"Yang Z, Yu L, Wang Z. PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chin J Cancer Res = Chung-Kuo Yen Cheng Yen Chiu. 2016;28(1):65\u201371. https:\/\/doi.org\/10.3978\/j.issn.1000-9604.2016.01.05. PubMed PMID: 27041928; PubMed Central PMCID: PMC4779752.","journal-title":"Chin J Cancer Res = Chung-Kuo Yen Cheng Yen Chiu"},{"issue":"6","key":"8043_CR26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.eururo.2018.08.019","volume":"74","author":"J McKiernan","year":"2018","unstructured":"McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, et al. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2\u201310 ng\/ml at Initial Biopsy. Eur Urol. 2018;74(6):731\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.019.","journal-title":"Eur Urol"},{"issue":"1","key":"8043_CR27","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1186\/s12885-025-14505-1","volume":"25","author":"Y Ahamed","year":"2025","unstructured":"Ahamed Y, Hossain M, Baral S, Al-Raiyan AU, Ashraf SB, Sun W. The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer. BMC Cancer. 2025;25(1):1264. https:\/\/doi.org\/10.1186\/s12885-025-14505-1. PubMed PMID: 40760471; PubMed Central PMCID: PMC12323064.","journal-title":"BMC Cancer"},{"key":"8043_CR28","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3389\/fonc.2019.01266","volume":"9","author":"U Satyal","year":"2019","unstructured":"Satyal U, Srivastava A, Abbosh PH. Urine Biopsy\u2014Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer. Front Oncol. 2019;9:1266. https:\/\/doi.org\/10.3389\/fonc.2019.01266.","journal-title":"Front Oncol"},{"issue":"1","key":"8043_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12943-023-01745-7","volume":"22","author":"M Li","year":"2023","unstructured":"Li M, Li L, Zheng J, Li Z, Li S, Wang K, et al. Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application. Mol Cancer. 2023;22(1):37. https:\/\/doi.org\/10.1186\/s12943-023-01745-7.","journal-title":"Mol Cancer"},{"issue":"1","key":"8043_CR30","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1186\/s12885-025-14900-8","volume":"25","author":"JF Kelly","year":"2025","unstructured":"Kelly JF, Samarska IV, Ramaekers B, Marcelissen T, Van Roermund JG, Aarts MJB, et al. Renal cell carcinoma detection: a systematic review in diagnostic urinary biomarkers. BMC Cancer. 2025;25(1):1672. https:\/\/doi.org\/10.1186\/s12885-025-14900-8. PubMed PMID: 41168704; PubMed Central PMCID: PMC12574123.","journal-title":"BMC Cancer"},{"issue":"3","key":"8043_CR31","doi-asserted-by":"publisher","first-page":"e14145","DOI":"10.1016\/j.heliyon.2023.e14145","volume":"9","author":"S Jiang","year":"2023","unstructured":"Jiang S, Liu Y, Xu Y, Sang X, Lu X. Research on liquid biopsy for cancer: A bibliometric analysis. Heliyon. 2023;9(3):e14145. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e14145.","journal-title":"Heliyon"},{"issue":"1","key":"8043_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s12672-024-01183-x","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Ma L, Chen H, Jin Z, Yang W, Qiao Y, et al. Knowledge mapping of exosomes in prostate cancer from 2003 to 2022: a bibliometric analysis. Discov Onc. 2024;15(1):307. https:\/\/doi.org\/10.1007\/s12672-024-01183-x.","journal-title":"Discov Onc"},{"key":"8043_CR33","doi-asserted-by":"publisher","first-page":"1574736","DOI":"10.3389\/fimmu.2025.1574736","volume":"16","author":"S Zhang","year":"2025","unstructured":"Zhang S, Zhao H, Wang K, Li L, Pan Q, Lu M, et al. Tracing the history of clinical practice of liquid biopsy: a bibliometric analysis. Front Immunol. 2025;16:1574736. https:\/\/doi.org\/10.3389\/fimmu.2025.1574736. PubMed PMID: 40433362; PubMed Central PMCID: PMC12105997.","journal-title":"Front Immunol"},{"key":"8043_CR34","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.2147\/JMDH.S554198","volume":"18","author":"J Ye","year":"2025","unstructured":"Ye J, Wu J, Hao X, Wang P, Xu Z, Liu L, et al. Global Research Trends and Frontiers in Upper Tract Urothelial Carcinoma: A Comprehensive Visualization and Bibliometric Analysis. JMDH. 2025;18:7103\u201320. 10.2147. \/JMDH.S554198 PubMed PMID: 41211028; PubMed Central PMCID: PMC12595954.","journal-title":"JMDH"},{"key":"8043_CR35","doi-asserted-by":"publisher","first-page":"121023","DOI":"10.1016\/j.techfore.2021.121023","volume":"172","author":"W Liu","year":"2021","unstructured":"Liu W. Caveats for the use of Web of Science Core Collection in old literature retrieval and historical bibliometric analysis. Technol Forecast Soc Chang. 2021;172:121023. https:\/\/doi.org\/10.1016\/j.techfore.2021.121023.","journal-title":"Technol Forecast Soc Chang"},{"issue":"1","key":"8043_CR36","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s11192-020-03697-x","volume":"126","author":"W Liu","year":"2021","unstructured":"Liu W. A matter of time: publication dates in Web of Science Core Collection. Scientometrics. 2021;126(1):849\u201357. https:\/\/doi.org\/10.1007\/s11192-020-03697-x.","journal-title":"Scientometrics"},{"key":"8043_CR37","unstructured":"Clarivate. What\u2019s next for JCR: defining \u2018Early Access\u2019 [Internet]. 2020 Nov 24 [cited 2026 Jan 3]. Available from: https:\/\/clarivate.com\/academia-government\/blog\/whats-next-for-jcr-defining-early-access\/."},{"issue":"3","key":"8043_CR38","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/asi.20317","volume":"57","author":"C Chen","year":"2006","unstructured":"Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol. 2006;57(3):359\u201377. https:\/\/doi.org\/10.1002\/asi.20317.","journal-title":"J Am Soc Inf Sci Technol"},{"issue":"2","key":"8043_CR39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523\u201338. https:\/\/doi.org\/10.1007\/s11192-009-0146-3. PubMed PMID: 20585380; PubMed Central PMCID: PMC2883932.","journal-title":"Scientometrics"},{"issue":"4","key":"8043_CR40","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","volume":"11","author":"M Aria","year":"2017","unstructured":"Aria M, Cuccurullo C. bibliometrix : An R-tool for comprehensive science mapping analysis. J Informetrics. 2017;11(4):959\u201375. https:\/\/doi.org\/10.1016\/j.joi.2017.08.007.","journal-title":"J Informetrics"},{"issue":"6","key":"8043_CR41","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"8043_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","volume":"70","author":"K Birkenkamp-Demtr\u00f6der","year":"2016","unstructured":"Birkenkamp-Demtr\u00f6der K, Nordentoft I, Christensen E, H\u00f8yer S, Reinert T, Vang S, et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol. 2016;70(1):75\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2016.01.007.","journal-title":"Eur Urol"},{"issue":"7","key":"8043_CR43","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","volume":"2","author":"J McKiernan","year":"2016","unstructured":"McKiernan J, Donovan MJ, O\u2019Neill V, Bentink S, Noerholm M, Belzer S, et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. Jama Oncol. 2016;2(7):882\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0097.","journal-title":"Jama Oncol"},{"issue":"1","key":"8043_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","volume":"70","author":"SA Tomlins","year":"2016","unstructured":"Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol. 2016;70(1):45\u201353. https:\/\/doi.org\/10.1016\/j.eururo.2015.04.039.","journal-title":"Eur Urol"},{"issue":"1","key":"8043_CR45","doi-asserted-by":"publisher","first-page":"e0147236","DOI":"10.1371\/journal.pone.0147236","volume":"11","author":"C Berrondo","year":"2016","unstructured":"Berrondo C, Flax J, Kucherov V, Siebert A, Osinski T, Rosenberg A, et al. Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS ONE. 2016;11(1):e0147236. https:\/\/doi.org\/10.1371\/journal.pone.0147236.","journal-title":"PLoS ONE"},{"key":"8043_CR46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2016.10.011","volume":"70","author":"T Skotland","year":"2017","unstructured":"Skotland T, Ekroos K, Kauhanen D, Simolin H, Seierstad T, Berge V, et al. Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers. Eur J Cancer. 2017;70:122\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2016.10.011. PubMed PMID: 27914242.","journal-title":"Eur J Cancer"},{"issue":"1","key":"8043_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3233\/BLC-170152","volume":"4","author":"IJ Russo","year":"2018","unstructured":"Russo IJ, Ju Y, Gordon NS, Zeegers MP, Cheng KK, James ND, et al. Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G\u2009>\u2009A\/T Mutation. Bladder Cancer. 2018;4(1):41\u20138. https:\/\/doi.org\/10.3233\/BLC-170152. PubMed PMID: 29430506; PubMed Central PMCID: PMC5798520.","journal-title":"Bladder Cancer"},{"issue":"1","key":"8043_CR48","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-017-0644-5","volume":"16","author":"A Di Meo","year":"2017","unstructured":"Di Meo A, Bartlett J, Cheng Y, Pasic MD, Yousef GM. Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer. 2017;16(1):80. https:\/\/doi.org\/10.1186\/s12943-017-0644-5.","journal-title":"Mol Cancer"},{"issue":"1","key":"8043_CR49","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-017-0726-4","volume":"16","author":"M Rodr\u00edguez","year":"2017","unstructured":"Rodr\u00edguez M, Bajo-Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, et al. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol Cancer. 2017;16(1):156. https:\/\/doi.org\/10.1186\/s12943-017-0726-4.","journal-title":"Mol Cancer"},{"issue":"5","key":"8043_CR50","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","volume":"70","author":"L Van Neste","year":"2016","unstructured":"Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker\u2013based risk score. Eur Urol. 2016;70(5):740\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2016.04.012.","journal-title":"Eur Urol"},{"issue":"4","key":"8043_CR51","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","volume":"73","author":"K Birkenkamp-Demtr\u00f6der","year":"2018","unstructured":"Birkenkamp-Demtr\u00f6der K, Christensen E, Nordentoft I, Knudsen M, Taber A, H\u00f8yer S, et al. Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. Eur Urol. 2018;73(4):535\u201340. https:\/\/doi.org\/10.1016\/j.eururo.2017.09.011. PubMed PMID: 28958829.","journal-title":"Eur Urol"},{"issue":"24","key":"8043_CR52","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1039\/C8LC01017J","volume":"18","author":"JT Smith","year":"2018","unstructured":"Smith JT, Wunsch BH, Dogra N, Ahsen ME, Lee K, Yadav KK, et al. Integrated nanoscale deterministic lateral displacement arrays for separation of extracellular vesicles from clinically-relevant volumes of biological samples. Lab Chip. 2018;18(24):3913\u201325. https:\/\/doi.org\/10.1039\/C8LC01017J.","journal-title":"Lab Chip"},{"key":"8043_CR53","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.3389\/fgene.2019.01150","volume":"10","author":"WJ Locke","year":"2019","unstructured":"Locke WJ, Guanzon D, Ma C, Liew YJ, Duesing KR, Fung KYC, et al. DNA Methylation Cancer Biomarkers: Translation to the Clinic. Front Genet. 2019;10:1150. https:\/\/doi.org\/10.3389\/fgene.2019.01150.","journal-title":"Front Genet"},{"issue":"1","key":"8043_CR54","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cas.13856","volume":"110","author":"W Usuba","year":"2019","unstructured":"Usuba W, Urabe F, Yamamoto Y, Matsuzaki J, Sasaki H, Ichikawa M, et al. Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci. 2019;110(1):408\u201319. https:\/\/doi.org\/10.1111\/cas.13856.","journal-title":"Cancer Sci"},{"issue":"3","key":"8043_CR55","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.euf.2016.09.007","volume":"4","author":"W Zhang","year":"2018","unstructured":"Zhang W, Ni M, Su Y, Wang H, Zhu S, Zhao A, et al. MicroRNAs in Serum Exosomes as Potential Biomarkers in Clear-cell Renal Cell Carcinoma. Eur Urol Focus. 2018;4(3):412\u20139. https:\/\/doi.org\/10.1016\/j.euf.2016.09.007. PubMed PMID: 28753793.","journal-title":"Eur Urol Focus"},{"issue":"3","key":"8043_CR56","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"8043_CR57","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Th\u00e9ry","year":"2018","unstructured":"Th\u00e9ry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicle. 2018;7(1):1535750. .1535750 PubMed PMID: 30637094; PubMed Central PMCID: PMC6322352.","journal-title":"J Extracell Vesicle"},{"issue":"6478","key":"8043_CR58","doi-asserted-by":"publisher","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. 10.1126. \/science.aau6977 PubMed PMID: 32029601; PubMed Central PMCID: PMC77176261.","journal-title":"Science"},{"issue":"4","key":"8043_CR59","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2021.01.074","volume":"32","author":"W Yu","year":"2021","unstructured":"Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32(4):466\u201377. https:\/\/doi.org\/10.1016\/j.annonc.2021.01.074. PubMed PMID: 33548389.","journal-title":"Ann Oncol"},{"issue":"1","key":"8043_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-022-01509-9","volume":"21","author":"D Yu","year":"2022","unstructured":"Yu D, Li Y, Wang M, Gu J, Xu W, Cai H, et al. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer. 2022;21(1):56. https:\/\/doi.org\/10.1186\/s12943-022-01509-9.","journal-title":"Mol Cancer"},{"issue":"9","key":"8043_CR61","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","volume":"19","author":"A Tivey","year":"2022","unstructured":"Tivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA \u2014 looking beyond the blood. Nat Rev Clin Oncol. 2022;19(9):600\u201312. https:\/\/doi.org\/10.1038\/s41571-022-00660-y.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"8043_CR62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","volume":"21","author":"SN Lone","year":"2022","unstructured":"Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022;21(1):79. https:\/\/doi.org\/10.1186\/s12943-022-01543-7.","journal-title":"Mol Cancer"},{"issue":"5","key":"8043_CR63","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1111\/cas.14000","volume":"110","author":"Y Hayashi","year":"2019","unstructured":"Hayashi Y, Fujita K, Matsuzaki K, Matsushita M, Kawamura N, Koh Y, et al. Diagnostic potential of TERT promoter and FGFR 3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma. Cancer Sci. 2019;110(5):1771\u20139. https:\/\/doi.org\/10.1111\/cas.14000. PubMed PMID: 30887605; PubMed Central PMCID: PMC6501003.","journal-title":"Cancer Sci"},{"key":"8043_CR64","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3389\/fonc.2020.00755","volume":"10","author":"Y Hayashi","year":"2020","unstructured":"Hayashi Y, Fujita K, Matsuzaki K, Eich ML, Tomiyama E, Matsushita M, et al. Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer. Front Oncol. 2020;10:755. https:\/\/doi.org\/10.3389\/fonc.2020.00755. PubMed PMID: 32509577; PubMed Central PMCID: PMC7250242.","journal-title":"Front Oncol"},{"key":"8043_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2018.10.033","volume":"85","author":"DN Palsgrove","year":"2019","unstructured":"Palsgrove DN, Taheri D, Springer SU, Cowan M, Guner G, Mendoza Rodriguez MA, et al. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Hum Pathol. 2019;85:1\u20139. https:\/\/doi.org\/10.1016\/j.humpath.2018.10.033. PubMed PMID: 30447301; PubMed Central PMCID: PMC6728909.","journal-title":"Hum Pathol"},{"issue":"6","key":"8043_CR66","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.euf.2025.06.009","volume":"11","author":"J Lee","year":"2025","unstructured":"Lee J, Chen F, Lopez-Beltran A, Necchi A, Cimadamore A, Spiess PE, et al. Urinary Tumor DNA\u2013based Liquid Biopsy in Bladder Cancer Management: A Systematic Review. Eur Urol Focus. 2025;11(6):978\u201390. https:\/\/doi.org\/10.1016\/j.euf.2025.06.009. PubMed PMID: 40753029.","journal-title":"Eur Urol Focus"},{"key":"8043_CR67","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.humpath.2022.06.005","volume":"133","author":"L Cheng","year":"2023","unstructured":"Cheng L, Zhang S, Wang M, Lopez-Beltran A. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management. Hum Pathol. 2023;133:56\u201375. https:\/\/doi.org\/10.1016\/j.humpath.2022.06.005. PubMed PMID: 35700749.","journal-title":"Hum Pathol"},{"issue":"2","key":"8043_CR68","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14737159.2020.1699791","volume":"20","author":"A Lopez-Beltran","year":"2020","unstructured":"Lopez-Beltran A, Cheng L, Gevaert T, Blanca A, Cimadamore A, Santoni M, et al. Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. Expert Rev Mol Diagn. 2020;20(2):231\u201343. https:\/\/doi.org\/10.1080\/14737159.2020.1699791. PubMed PMID: 31795775.","journal-title":"Expert Rev Mol Diagn"},{"issue":"18","key":"8043_CR69","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Sethi H, Shchegrova S, Salari R, Nordentoft I, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. JCO. 2019;37(18):1547\u201357. 10.1200. \/JCO.18.02052 PubMed PMID: 31059311.","journal-title":"JCO"},{"issue":"6","key":"8043_CR70","doi-asserted-by":"publisher","first-page":"e0157566","DOI":"10.1371\/journal.pone.0157566","volume":"11","author":"OE Bryzgunova","year":"2016","unstructured":"Bryzgunova OE, Zaripov MM, Skvortsova TE, Lekchnov EA, Grigor\u2019eva AE, Zaporozhchenko IA, et al. Comparative study of extracellular vesicles from the urine of healthy individuals and prostate cancer patients. PLoS ONE. 2016;11(6):e0157566. https:\/\/doi.org\/10.1371\/journal.pone.0157566.","journal-title":"PLoS ONE"},{"issue":"8","key":"8043_CR71","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Albiges L, Bex A, Comperat E, Gr\u00fcnwald V, Kanesvaran R, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(8):692\u2013706. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.537. PubMed PMID: 38788900.","journal-title":"Ann Oncol"},{"issue":"1","key":"8043_CR72","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al. Early Detection of Prostate Cancer: AUA\/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023;210(1):46\u201353. https:\/\/doi.org\/10.1097\/JU.0000000000003491. PubMed PMID: 37096582 PubMed Central PMCID: PMC11060750.","journal-title":"J Urol"},{"issue":"1","key":"8043_CR73","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/JU.0000000000003492","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al. Early Detection of Prostate Cancer: AUA\/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol. 2023;210(1):54\u201363. https:\/\/doi.org\/10.1097\/JU.0000000000003492. PubMed PMID: 37096575; PubMed Central PMCID: PMC11321723.","journal-title":"J Urol"},{"key":"8043_CR74","unstructured":"European Association of Urology. EAU\u2013EANM\u2013ESTRO\u2013ESUR\u2013ISUP\u2013SIOG Guidelines on Prostate Cancer. Limited Update March 2025 [Internet]. [cited 2026 Jan 21]. Available from: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf"},{"key":"8043_CR75","doi-asserted-by":"publisher","first-page":"270457","DOI":"10.1155\/2013\/270457","volume":"2013","author":"V Casadio","year":"2013","unstructured":"Casadio V, Calistri D, Salvi S, Gunelli R, Carretta E, Amadori D, et al. Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study. Biomed Res Int. 2013;2013:270457. https:\/\/doi.org\/10.1155\/2013\/270457. PubMed PMID: 23509700; PubMed Central PMCID: PMC3586456.","journal-title":"Biomed Res Int"},{"issue":"1","key":"8043_CR76","doi-asserted-by":"publisher","first-page":"574120","DOI":"10.1155\/2015\/574120","volume":"2015","author":"S Salvi","year":"2015","unstructured":"Salvi S, Gurioli G, Martignano F, Foca F, Gunelli R, Cicchetti G, et al. Urine cell-free DNA integrity analysis for early detection of prostate cancer patients. Dis Markers. 2015;2015(1):574120. https:\/\/doi.org\/10.1155\/2015\/574120.","journal-title":"Dis Markers"},{"issue":"5","key":"8043_CR77","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00345-010-0623-6","volume":"29","author":"MA Liss","year":"2011","unstructured":"Liss MA, Santos R, Osann K, Lau A, Ahlering TE, Ornstein DK. PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. World J Urol. 2011;29(5):683\u20138. https:\/\/doi.org\/10.1007\/s00345-010-0623-6. PubMed PMID: 21152924; PubMed Central PMCID: PMC3189407.","journal-title":"World J Urol"},{"issue":"1","key":"8043_CR78","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13148-019-0716-z","volume":"11","author":"A Bakavicius","year":"2019","unstructured":"Bakavicius A, Daniunaite K, Zukauskaite K, Barisiene M, Jarmalaite S, Jankevicius F. Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging. Clin Epigenet. 2019;11(1):115. https:\/\/doi.org\/10.1186\/s13148-019-0716-z.","journal-title":"Clin Epigenet"},{"issue":"2","key":"8043_CR79","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.juro.2016.08.081","volume":"197","author":"F Zhao","year":"2017","unstructured":"Zhao F, Olkhov-Mitsel E, Van Der Kwast T, Sykes J, Zdravic D, Venkateswaran V, et al. Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance. J Urol. 2017;197(2):335\u201341. Located at: Philadelphia, PA. https:\/\/doi.org\/10.1016\/j.juro.2016.08.081","journal-title":"J Urol"},{"issue":"21","key":"8043_CR80","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.3390\/cancers17213425","volume":"17","author":"Z Yang","year":"2025","unstructured":"Yang Z, Song F, Zhong J. Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance. Cancers. 2025;17(21):3425. doi:10.3390\/cancers17213425 PubMed PMID: 41228219; PubMed Central PMCID: PMC12607409.","journal-title":"Cancers"},{"issue":"4","key":"8043_CR81","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline: 2024 Amendment. J Urol. 2024;211(4):533\u20138. https:\/\/doi.org\/10.1097\/JU.0000000000003846.","journal-title":"J Urol"},{"key":"8043_CR82","unstructured":"European Association of Urology. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS) \u2013 Limited Update March 2025 [Internet]. [cited 2026 Jan 21]. Available from: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2025.pdf"},{"issue":"4","key":"8043_CR83","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/bjc.2017.210","volume":"117","author":"F Descotes","year":"2017","unstructured":"Descotes F, Kara N, Decaussin-Petrucci M, Piaton E, Geiguer F, Rodriguez-Lafrasse C, et al. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. Br J Cancer. 2017;117(4):583\u20137. https:\/\/doi.org\/10.1038\/bjc.2017.210.","journal-title":"Br J Cancer"},{"issue":"3","key":"8043_CR84","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4274\/uob.galenos.2024.2024.3.3","volume":"23","author":"M Kars","year":"2024","unstructured":"Kars M, \u00c7etin M, Toper MH, Filinte D, \u00c7am K. Contemporary Role of Urine Cytology in Bladder Cancer. uob. 2024;23(3):73\u20137. https:\/\/doi.org\/10.4274\/uob.galenos.2024.2024.3.3.","journal-title":"uob"},{"issue":"12","key":"8043_CR85","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.1172\/JCI139597","volume":"130","author":"X Chen","year":"2020","unstructured":"Chen X, Zhang J, Ruan W, Huang M, Wang C, Wang H, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J Clin Invest. 2020;130(12):6278\u201389. https:\/\/doi.org\/10.1172\/JCI139597. PubMed PMID: 32817589; PubMed Central PMCID: PMC7685755.","journal-title":"J Clin Invest"},{"issue":"4","key":"8043_CR86","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1158\/2159-8290.CD-18-0825","volume":"9","author":"JC Dudley","year":"2019","unstructured":"Dudley JC, Schroers-Martin J, Lazzareschi DV, Shi WY, Chen SB, Esfahani MS, et al. Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discov. 2019;9(4):501\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0825. PubMed PMID: 30578357; PubMed Central PMCID: PMC6467650.","journal-title":"Cancer Discov"},{"issue":"7","key":"8043_CR87","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nm.3870","volume":"21","author":"G Siravegna","year":"2015","unstructured":"Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):795\u2013801. https:\/\/doi.org\/10.1038\/nm.3870. PubMed PMID: 26030179; PubMed Central PMCID: PMC4868598.","journal-title":"Nat Med"},{"issue":"Pt 1","key":"8043_CR88","doi-asserted-by":"publisher","first-page":"146175","DOI":"10.1016\/j.ijbiomac.2025.146175","volume":"321","author":"S Ahmad","year":"2025","unstructured":"Ahmad S, Raza K. Evaluating the polypharmacological potential of cosmetic preservative imidurea against lung cancer-associated EGFR, CDK2, STAT3, BCL2, p53, and ABCB1 proteins. Int J Biol Macromol. 2025;321(Pt 1):146175. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.146175. PubMed PMID: 40706931.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"8043_CR89","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.juro.2016.12","volume":"197","author":"L Kavalieris","year":"2017","unstructured":"Kavalieris L, O\u2019Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E, et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol. 2017;197(6):1419\u201326. https:\/\/doi.org\/10.1016\/j.juro.2016.12. .010 PubMed PMID: 27986532.","journal-title":"J Urol"},{"issue":"1","key":"8043_CR90","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40487-018-0059-5","volume":"6","author":"T Lough","year":"2018","unstructured":"Lough T, Luo Q, O\u2019Sullivan P, Chemasl\u00e9 C, Stotzer M, Suttie J, et al. Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician\u2013Patient Real-World Clinical Data Analysis. Oncol Ther. 2018;6(1):73\u201385. https:\/\/doi.org\/10.1007\/s40487-018-0059-5. PubMed PMID: 32700139; PubMed Central PMCID: PMC7359999.","journal-title":"Oncol Ther"},{"issue":"1","key":"8043_CR91","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41746-024-01088-7","volume":"7","author":"JCC Kwong","year":"2024","unstructured":"Kwong JCC, Wu J, Malik S, Khondker A, Gupta N, Bodnariuc N, et al. Predicting non-muscle invasive bladder cancer outcomes using artificial intelligence: a systematic review using APPRAISE-AI. npj Digit Med. 2024;7(1):98. https:\/\/doi.org\/10.1038\/s41746-024-01088-7.","journal-title":"npj Digit Med"},{"issue":"3","key":"8043_CR92","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3892\/ijo.2025.5724","volume":"66","author":"X Wan","year":"2025","unstructured":"Wan X, Wang D, Zhang X, Xu M, Huang Y, Qin W, et al. Unleashing the power of urine\u2013based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review). Int J Oncol. 2025;66(3):18. https:\/\/doi.org\/10.3892\/ijo.2025.5724.","journal-title":"Int J Oncol"},{"issue":"4","key":"8043_CR93","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41391-021-00367-8","volume":"24","author":"RJ Hendriks","year":"2021","unstructured":"Hendriks RJ, Van Der Leest MMG, Isra\u00ebl B, Hannink G, YantiSetiasti A, Cornel EB, et al. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-na\u00efve men. Prostate Cancer Prostatic Dis. 2021;24(4):1110\u20139. https:\/\/doi.org\/10.1038\/s41391-021-00367-8.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"8043_CR94","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-024-01974-4","volume":"23","author":"J Wu","year":"2024","unstructured":"Wu J, Lin Y, Yang K, Liu X, Wang H, Yu T, et al. Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial. Mol Cancer. 2024;23(1):57. https:\/\/doi.org\/10.1186\/s12943-024-01974-4. PubMed PMID: 38504268; PubMed Central PMCID: PMC10949661.","journal-title":"Mol Cancer"},{"issue":"3","key":"8043_CR95","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/JU.0000000000002748","volume":"208","author":"A Territo","year":"2022","unstructured":"Territo A, Gallioli A, Diana P, Boissier R, Fontana M, Gaya JM, et al. DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial. J Urol. 2022;208(3):570\u20139. 10. 1097\/JU.0000000000002748 PubMed PMID: 35549312.","journal-title":"J Urol"},{"key":"8043_CR96","doi-asserted-by":"publisher","first-page":"e32143","DOI":"10.7554\/eLife.32143","volume":"7","author":"SU Springer","year":"2018","unstructured":"Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. eLife. 2018;7:e32143. 10. 7554\/eLife.32143 PubMed PMID: 29557778; PubMed Central PMCID: PMC5860864.","journal-title":"eLife"},{"issue":"16","key":"8043_CR97","doi-asserted-by":"publisher","first-page":"8846","DOI":"10.3390\/ijms22168846","volume":"22","author":"R Kubiliute","year":"2021","unstructured":"Kubiliute R, Jarmalaite S. Epigenetic Biomarkers of Renal Cell Carcinoma for Liquid Biopsy Tests. IJMS. 2021;22(16):8846. doi:10.3390\/ijms22168846 PubMed PMID: 34445557; PubMed Central PMCID: PMC8396354.","journal-title":"IJMS"},{"issue":"7","key":"8043_CR98","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41591-020-0933-1","volume":"26","author":"PV Nuzzo","year":"2020","unstructured":"Nuzzo PV, Berchuck JE, Korthauer K, Spisak S, Nassar AH, Abou Alaiwi S, et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020;26(7):1041\u20133. https:\/\/doi.org\/10.1038\/s41591-020-0933-1. PubMed PMID: 32572266; PubMed Central PMCID: PMC8288043.","journal-title":"Nat Med"},{"key":"8043_CR99","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clinbiochem.2019.10.002","volume":"75","author":"A Di Meo","year":"2020","unstructured":"Di Meo A, Brown MD, Finelli A, Jewett MAS, Diamandis EP, Yousef GM. Prognostic urinary miRNAs for the assessment of small renal masses. Clin Biochem. 2020;75:15\u201322. https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.10.002. PubMed PMID: 31672647.","journal-title":"Clin Biochem"},{"issue":"1","key":"8043_CR100","doi-asserted-by":"publisher","first-page":"21290","DOI":"10.1038\/s41598-020-77774-9","volume":"10","author":"G Cochetti","year":"2020","unstructured":"Cochetti G, Cari L, Nocentini G, Maul\u00e0 V, Suvieri C, Cagnani R, et al. Detection of urinary miRNAs for diagnosis of clear cell renal cell carcinoma. Sci Rep. 2020;10(1):21290. https:\/\/doi.org\/10.1038\/s41598-020-77774-9. PubMed PMID: 33277569; PubMed Central PMCID: PMC7718885.","journal-title":"Sci Rep"},{"issue":"16","key":"8043_CR101","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1007\/s00216-018-1059-x","volume":"410","author":"J Nizio\u0142","year":"2018","unstructured":"Nizio\u0142 J, Bonifay V, Ossoli\u0144ski K, Ossoli\u0144ski T, Ossoli\u0144ska A, Sunner J, et al. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA. Anal Bioanal Chem. 2018;410(16):3859\u201369. https:\/\/doi.org\/10.1007\/s00216-018-1059-x. PubMed PMID: 29658093; PubMed Central PMCID: PMC5956006.","journal-title":"Anal Bioanal Chem"},{"issue":"10","key":"8043_CR102","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/metabo14100546","volume":"14","author":"KL Holbrook","year":"2024","unstructured":"Holbrook KL, Quaye GE, Noriega Landa E, Su X, Gao Q, Williams H, et al. Detection and Validation of Organic Metabolites in Urine for Clear Cell Renal Cell Carcinoma Diagnosis. Metabolites. 2024;14(10):546. https:\/\/doi.org\/10.3390\/metabo14100546. PubMed PMID: 39452927; PubMed Central PMCID: PMC11509871.","journal-title":"Metabolites"},{"issue":"2","key":"8043_CR103","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.euo.2019.07.011","volume":"4","author":"K Lommen","year":"2021","unstructured":"Lommen K, Vaes N, Aarts MJ, Van Roermund JG, Schouten LJ, Oosterwijk E, et al. Diagnostic DNA Methylation Biomarkers for Renal Cell Carcinoma: A Systematic Review. Eur Urol Oncol. 2021;4(2):215\u201326. https:\/\/doi.org\/10.1016\/j.euo.2019.07.011.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"8043_CR104","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer: current status, challenges and future prospects. Sig Transduct Target Ther. 2024;9(1):336. https:\/\/doi.org\/10.1038\/s41392-024-02021-w.","journal-title":"Sig Transduct Target Ther"},{"issue":"9","key":"8043_CR105","doi-asserted-by":"publisher","first-page":"101736","DOI":"10.1016\/j.xcrm.2024.101736","volume":"5","author":"A Tivey","year":"2024","unstructured":"Tivey A, Lee RJ, Clipson A, Hill SM, Lorigan P, Rothwell DG, et al. Mining nucleic acid omics to boost liquid biopsy in cancer. Cell Rep Med. 2024;5(9):101736. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101736. PubMed PMID: 39293399.","journal-title":"Cell Rep Med"},{"key":"8043_CR106","doi-asserted-by":"publisher","first-page":"1331215","DOI":"10.3389\/fonc.2024.1331215","volume":"14","author":"W Wang","year":"2024","unstructured":"Wang W, Zhen S, Ping Y, Wang L, Zhang Y. Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring. Front Oncol. 2024;14:1331215. https:\/\/doi.org\/10.3389\/fonc.2024.1331215.","journal-title":"Front Oncol"},{"key":"8043_CR107","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.jlb.2023.100126","volume":"2","author":"OA Bamodu","year":"2023","unstructured":"Bamodu OA, Chung CC, Pisanic TR. Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine. J Liquid Biopsy. 2023;2:100126. https:\/\/doi.org\/10.1016\/j.jlb.2023.100126. PubMed PMID: 40028482; PubMed Central PMCID: PMC11863985.","journal-title":"J Liquid Biopsy"},{"key":"8043_CR108","doi-asserted-by":"publisher","unstructured":"Ahmad S, Raza K. DrLungker: a deep ensemble learning framework for predicting anti-lung cancer compound activity and validating multitarget potency through WaterMap, DFT, MD simulations, and MM-GBSA analysis. Adv Theor Simul. 2025;e01550. https:\/\/doi.org\/10.1002\/adts.202501550.","DOI":"10.1002\/adts.202501550"},{"issue":"10","key":"8043_CR109","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1080\/1061186X.2025.2530656","volume":"33","author":"S Ahmad","year":"2025","unstructured":"Ahmad S, Shah SNA, Parveen R, Raza K. Machine learning for genomic profiling and drug discovery in personalised lung cancer therapeutics. J Drug Target. 2025;33(10):1807\u201326. 2025.2530656 PubMed PMID: 40643949.","journal-title":"J Drug Target"},{"issue":"1","key":"8043_CR110","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41698-022-00345-w","volume":"7","author":"PS Chauhan","year":"2023","unstructured":"Chauhan PS, Shiang A, Alahi I, Sundby RT, Feng W, Gungoren B, et al. Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients. npj Precis Onc. 2023;7(1):6. https:\/\/doi.org\/10.1038\/s41698-022-00345-w.","journal-title":"npj Precis Onc"},{"issue":"2","key":"8043_CR111","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh JA, Goberdhan DCI, O\u2019Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicle. 2024;13(2):e12404. https:\/\/doi.org\/10.1002\/jev2.12404.","journal-title":"J Extracell Vesicle"},{"issue":"1","key":"8043_CR112","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s43856-025-00885-9","volume":"5","author":"M Perachino","year":"2025","unstructured":"Perachino M, Ortiz C, Carmona J, Saura C, Vivancos A. Expanding screening through the use of liquid biopsy for early cancer detection. Commun Med. 2025;5(1):167. https:\/\/doi.org\/10.1038\/s43856-025-00885-9.","journal-title":"Commun Med"},{"issue":"10","key":"8043_CR113","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/oncolo\/oyae230","volume":"29","author":"M Machaalani","year":"2024","unstructured":"Machaalani M, Eid M, Semaan K, El Hajj Chehade R, Nawfal R, Baca SC, et al. Liquid biopsy in renal cell carcinoma. Oncologist. 2024;29(10):821\u20133. https:\/\/doi.org\/10.1093\/oncolo\/oyae230. PubMed PMID: 39187381; PubMed Central PMCID: PMC11448876.","journal-title":"Oncologist"},{"key":"8043_CR114","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3389\/fonc.2019.00663","volume":"9","author":"X Liu","year":"2019","unstructured":"Liu X, Zhang M, Liu X, Sun H, Guo Z, Tang X, et al. Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC. Front Oncol. 2019;9:663. https:\/\/doi.org\/10.3389\/fonc.2019.00663.","journal-title":"Front Oncol"},{"issue":"5","key":"8043_CR115","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/JU.0000000000003188","volume":"209","author":"A Ghoreifi","year":"2023","unstructured":"Ghoreifi A, Ladi-Seyedian SS, Piatti P, Chew YC, Jara B, Sanossian L, et al. A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study. J Urol. 2023;209(5):854\u201362. 10. 1097\/JU.0000000000003188 PubMed PMID: 36795966.","journal-title":"J Urol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08043-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08043-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08043-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:37:09Z","timestamp":1774867029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08043-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8043"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08043-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8287024\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"437"}}